iMOST® Haematology Analyser
iMOST® Haematology Analyser
Lab-quality FBC results from a single drop of capillary blood, delivered in under 5 minutes at the point of care.
Introducing the iMOST®
Using advanced micro- and nanotechnology combined with biochemical analysis and computer vision, it provides accurate, quantitative measurement of key haematology parameters, enabling faster clinical decisions without reliance on central laboratory processing.
Why iMOST?
- Full blood counts in under 5 minutes
- Lab-comparable accuracy without central lab delays
- Supports rapid decision-making in ED, primary care, and wards
- Works with ~10µL samples — ideal for limited/fragile patients
- Improves patient flow and reduces retesting
Parameters Measured
- Haemoglobin (HGB)
- White Blood Cell Count (WBC)
- Platelet Count (PLT)
- Red Blood Cell Count (RBC)
- White Blood Cell 5-Part Differential: NEU# & NEU%; LYM# & LYM%; MON# & MON%; EOS# & EOS%; BAS# & BAS%
- Mean Corpuscular Volume (MCV)
- Haematocrit (HCT)
- Mean Corpuscular Haemoglobin Concentration (MCHC)，
- Mean Corpuscular Haemoglobin (MCH)
- Red Blood Cell Distribution Width (RDW)
ONE sample cartridge format and ONE instrument, performs different types of assays, samples and biomarkers (including cytology and pathology).
A game-changing solution to meet the critical unmet need
A Note from Essenlix
Traditional clinical laboratory testing often depends on complex instrumentation, specialised operators and dedicated laboratory environments. While these systems are designed to deliver the high levels of precision required for accurate testing, they can also make testing more costly, time-consuming and less accessible. This conventional approach is based on what Essenlix refers to as the “precision paradigm.”
Essenlix has developed a different approach: the “intelligent fault-tolerant paradigm.” Together with a range of proprietary innovations, this framework is designed to enable clinical laboratory-quality testing using simpler, more accessible devices that can continue to perform reliably despite variations in samples, devices, processes and operating conditions.
A further challenge in conventional point-of-care testing is the need for different instruments, cartridges and sample-handling systems for different types of tests. The iMOST® technology platform is designed to overcome this limitation through a versatile, integrated approach
Using a common platform, iMOST® technology can accommodate a wide range of sample types, including blood, saliva, urine, swabs, sputum, breath, mucus and tissue. The platform is designed to support a broad range of testing methodologies, including immunoassays, colorimetric assays, cytology, pathology and nucleic-acid testing, across biomarkers such as cells, proteins, nucleic acids and small molecules. (Some of these applications are currently in development and are not yet commercially available.)
iMOST® incorporates several innovations aimed at making diagnostic testing faster, simpler and more accessible. Depending on the application, it can operate with very small sample volumes, typically 10 µL, and deliver results within minutes. Integration with mobile technology enables real-time data processing, monitoring and calibration.
The platform is designed to be easy to operate, reliable, low-maintenance and cost-effective. Its intelligent fault-tolerant architecture also enables iMOST® readers to be compact and suitable for efficient large-scale manufacturing.
iMOST® — Instant Mobile Self-Test — represents a new approach to diagnostic testing, integrating advanced nanotechnology, imaging, Nano-Enabled Artificial Intelligence and Machine Learning (NEAM), together with innovative biological and chemical processes, into a compact diagnostic platform.